-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Relay Therapeutics, Raises Price Target to $22

Benzinga·03/13/2026 13:04:35
Listen to the news
Guggenheim analyst Brad Canino maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and raises the price target from $15 to $22.